615 related articles for article (PubMed ID: 28879083)
1. Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
Falahati F; Ferreira D; Muehlboeck JS; Eriksdotter M; Simmons A; Wahlund LO; Westman E
Neuroimage Clin; 2017; 16():418-428. PubMed ID: 28879083
[TBL] [Abstract][Full Text] [Related]
2. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
3. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
5. CSF Apo-E levels associate with cognitive decline and MRI changes.
Toledo JB; Da X; Weiner MW; Wolk DA; Xie SX; Arnold SE; Davatzikos C; Shaw LM; Trojanowski JQ;
Acta Neuropathol; 2014 May; 127(5):621-32. PubMed ID: 24385135
[TBL] [Abstract][Full Text] [Related]
6. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
[TBL] [Abstract][Full Text] [Related]
7. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
[TBL] [Abstract][Full Text] [Related]
8. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
9. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
[TBL] [Abstract][Full Text] [Related]
10. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
[TBL] [Abstract][Full Text] [Related]
11. Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
Kester MI; Verwey NA; van Elk EJ; Blankenstein MA; Scheltens P; van der Flier WM
Neurobiol Aging; 2011 Aug; 32(8):1372-8. PubMed ID: 19748159
[TBL] [Abstract][Full Text] [Related]
12. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
13. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Löwe LC; Gaser C; Franke K;
PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
[TBL] [Abstract][Full Text] [Related]
14. Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease.
Soldan A; Pettigrew C; Lu Y; Wang MC; Selnes O; Albert M; Brown T; Ratnanather JT; Younes L; Miller MI;
Hum Brain Mapp; 2015 Jul; 36(7):2826-41. PubMed ID: 25879865
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
16. A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia.
Ferreira D; Falahati F; Linden C; Buckley RF; Ellis KA; Savage G; Villemagne VL; Rowe CC; Ames D; Simmons A; Westman E
Sci Rep; 2017 Mar; 7():44368. PubMed ID: 28287184
[TBL] [Abstract][Full Text] [Related]
17. Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations.
Orellana C; Ferreira D; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Lovestone S; Simmons A; Wahlund LO; Westman E;
Neurodegener Dis; 2016; 16(1-2):77-86. PubMed ID: 26726737
[TBL] [Abstract][Full Text] [Related]
18. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
[TBL] [Abstract][Full Text] [Related]
19. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
[TBL] [Abstract][Full Text] [Related]
20. APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease.
Morgen K; Frölich L; Tost H; Plichta MM; Kölsch H; Rakebrandt F; Rienhoff O; Jessen F; Peters O; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Hampel H; Teipel SJ; Pantel J; Heuser I; Wiltfang J; Rüther E; Kornhuber J; Maier W; Meyer-Lindenberg A
J Alzheimers Dis; 2013; 37(2):389-401. PubMed ID: 23948881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
